Full metadata record

DC FieldValueLanguage
dc.contributor.author이헌주ko
dc.contributor.author김병익[김병익]ko
dc.contributor.author최종영[최종영]ko
dc.contributor.author김동준[김동준]ko
dc.contributor.author황재석[황재석]ko
dc.contributor.author조몽[조몽]ko
dc.contributor.authorHyun Young Woo[Hyun Young Woo]ko
dc.contributor.authorSeung Kew Yoon[Seung Kew Yoon]ko
dc.contributor.authorDong Jin Suh[Dong Jin Suh]ko
dc.contributor.authorSeung Woon Paik[Seung Woon Paik]ko
dc.date.accessioned2015-12-17T04:13:42Z-
dc.date.available2015-12-17T04:13:42Z-
dc.date.created2015-11-13-
dc.date.issued201406-
dc.identifier.citationClinical and molecular hepatology, v.20, no.2, pp.168 - 176-
dc.identifier.issn2287-285X-
dc.identifier.urihttp://hdl.handle.net/YU.REPOSITORY/31866-
dc.identifier.urihttp://dx.doi.org/10.3350/cmh.2014.20.2.168-
dc.description.abstractBACKGROUND/AIMS: Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after ADV rescue therapy in decompensated patients infected with lamivudine-resistant HBV.METHODS: In total, 128 patients with a decompensated state and lamivudine-resistant HBV were treated with ADV at a dosage of 10 mg/day for a median of 33 months in this multicenter cohort study.RESULTS: Following ADV treatment, 86 (72.3%) of 119 patients experienced a decrease in Child-Pugh score of at least 2 points, and the overall end-stage liver disease score decreased from 16��5 to 14��10 (mean �� SD, P<0.001) during the follow-up period. With ADV treatment, 67 patients (56.3%) had undetectable serum HBV DNA (detection limit, 0.5 pg/mL). Virologic breakthrough occurred in 38 patients (36.1%) and 9 patients had a suboptimal ADV response. The overall survival rate was 89.9% (107/119), and a suboptimal response to ADV treatment was associated with both no improvement in Child-Pugh score (��2 points; P=0.001) and high mortality following ADV rescue therapy (P=0.012).CONCLUSIONS: Three years of ADV treatment was effective and safe in decompensated patients with lamivudine-resistant HBV.-
dc.language영어-
dc.subjectadefovir-
dc.subjectadenine-
dc.subjectantivirus agent-
dc.subjecthepatitis B(e) antigen-
dc.subjectlamivudine-
dc.subjectphosphonic acid derivative-
dc.subjectvirus DNA-
dc.subjectadult-
dc.subjectaged-
dc.subjectanalogs and derivatives-
dc.subjectantiviral resistance-
dc.subjectblood-
dc.subjectclinical trial-
dc.subjectcohort analysis-
dc.subjectcomplication-
dc.subjectfemale-
dc.subjectgenetics-
dc.subjecthepatitis B-
dc.subjectHepatitis B virus-
dc.subjecthuman-
dc.subjectliver cirrhosis-
dc.subjectmale-
dc.subjectmiddle aged-
dc.subjectmortality-
dc.subjectmulticenter study-
dc.subjectretrospective study-
dc.subjectrisk-
dc.subjectseverity of illness index-
dc.subjectsurvival rate-
dc.subjectAdenine-
dc.subjectAdult-
dc.subjectAged-
dc.subjectAntiviral Agents-
dc.subjectCohort Studies-
dc.subjectDNA, Viral-
dc.subjectDrug Resistance, Viral-
dc.subjectFemale-
dc.subjectHepatitis B-
dc.subjectHepatitis B e Antigens-
dc.subjectHepatitis B virus-
dc.subjectHumans-
dc.subjectLamivudine-
dc.subjectLiver Cirrhosis-
dc.subjectMale-
dc.subjectMiddle Aged-
dc.subjectOdds Ratio-
dc.subjectOrganophosphonates-
dc.subjectRetrospective Studies-
dc.subjectSeverity of Illness Index-
dc.subjectSurvival Rate-
dc.titleRescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus-
dc.typeArticle-
dc.identifier.scopusid2-s2.0-84925228016-
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE